Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Clinical Trial Evidence vs Online Claims

Trial results and labels for licensed GLP-1 medicines can be read at source. This page sets out what three large trials reported, what the Wegovy label warns about, and what the MHRA says about fake products.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

What three large trials reported

  • STEP 1 (Wilding 2021, NEJM, PMID 33567185): 1,961 adults with obesity or overweight, without diabetes, given semaglutide 2.4 mg or placebo once weekly for 68 weeks plus lifestyle intervention. Mean weight change was -14.9% with semaglutide and -2.4% with placebo. More people in the semaglutide group stopped treatment because of gastrointestinal events (4.5% against 0.8%).
  • SURMOUNT-1 (Jastreboff 2022, NEJM, PMID 35658024): 2,539 adults without diabetes given tirzepatide 5, 10 or 15 mg or placebo once weekly for 72 weeks, including a 20-week dose-escalation period. Mean weight change was -15.0%, -19.5% and -20.9% with the three doses and -3.1% with placebo. Adverse events led to stopping in 4.3%, 7.1%, 6.2% and 2.6% of the four groups.
  • SELECT (Lincoff 2023, NEJM, PMID 37952131): 17,604 adults aged 45 or over with established cardiovascular disease and a BMI of 27 or more, without diabetes, given semaglutide 2.4 mg or placebo once weekly; mean follow-up 39.8 months. The primary cardiovascular outcome occurred in 6.5% on semaglutide and 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). Adverse events led to permanent discontinuation in 16.6% on semaglutide and 8.2% on placebo.

Each abstract names the manufacturer as funder: Novo Nordisk for STEP 1 and SELECT, Eli Lilly for SURMOUNT-1. Nausea and diarrhoea were the most common adverse events in STEP 1, and gastrointestinal events in SURMOUNT-1.

What these trials do not cover

  • Time beyond the trial: 68 weeks in STEP 1, 72 weeks in SURMOUNT-1 and a mean 39.8 months of follow-up in SELECT.
  • People outside the populations enrolled: all three excluded people with diabetes, and SELECT enrolled only people with established cardiovascular disease.
  • Use with other GLP-1 medicines. The current Wegovy label (DailyMed set id ee06186f, version effective 18 June 2026) says: “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”

What the Wegovy label warns about

The same label opens with a boxed warning, “WARNING: RISK OF THYROID C-CELL TUMORS”: “In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.” It adds that it is unknown whether Wegovy causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans. Its Contraindications section (section 4) lists two conditions: a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and “a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet”. Its Warnings and Precautions also cover acute pancreatitis and severe gastrointestinal adverse reactions.

Pregnancy

In the label’s highlights, under pregnancy: “May cause fetal harm.” and “For patients receiving WEGOVY for CV risk reduction or weight reduction, discontinue WEGOVY when pregnancy is recognized.” and “For patients with MASH, use during pregnancy only if the potential benefit justifies the potential risk to the fetus.” Section 8.3 says: “Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”.

What the MHRA says about products sold outside prescribing

The MHRA’s GLP-1 page (GOV.UK, updated 5 February 2026) says: “GLP-1 medicines should not be bought from unregulated sellers such as beauty salons or via social media, or from anywhere without a prior consultation with a healthcare professional. We have had reports of people experiencing severe side effects from fake GLP-1 medicines.” It also says: “Products supplied as a powder in vials which must be mixed with a liquid prior to injection are not authorised and pose significant health risks.” (MHRA, GOV.UK).

How PeptideStacks frames this

We describe what the trials showed, in their populations and at their doses, with their limitations. This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Published: 2026-06-20Last updated: 2026-11-06

If you spot an error or have new evidence to suggest, please use our corrections policy.